Drugs / Anti-CD45
Anti-CD45
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00078546 | Sep 2003 → Jan 2007 | Epstein-Barr virus infection, nasopharyngeal carcinoma | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT00057005 | Feb 2003 → Oct 2009 | leukemia | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT00579137 | Oct 2007 → Oct 2009 | Wiskott-Aldrich syndrome, severe combined immunodeficiency | Baylor College of Medicine | Terminated | No outcome recorded |
| Phase 1/2 | NCT00056966 | Nov 2002 → May 2005 | hematopoietic and lymphoid cell neoplasm | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT00056979 | Jun 2002 → Jun 2003 | inborn errors of metabolism | Baylor College of Medicine | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-CD45 | “Anti-CD45 is a combination in equal amounts (weight for volume) of two monoclonal antibodies that are directed to non-overlapping epitopes on human CD45.” NCT00078546 ↗ |
| Known as | YTH 54 | “Anti-CD45 (YTH-24 & YTH 54) and ANTI-CD52 (CAMPATH-1H) Monoclonal Antibody Conditioning Regimen” NCT00056979 ↗ |
| Known as | YTH-24 | “Anti-CD45 (YTH-24 & YTH 54) and ANTI-CD52 (CAMPATH-1H) Monoclonal Antibody Conditioning Regimen” NCT00056979 ↗ |
| Action | Deplete | “Anti-CD45 may help in eradicating residual malignant cells.” NCT00056966 ↗ |
| Modality | Protein / enzyme biologic | “Anti-CD45 and CAMPATH-1H are antibodies against certain types of blood cells” NCT00056966 ↗ |
| Route | Intravenous | “Anti-CD45 will be given as a daily IV infusion for 4 days.” NCT00056966 ↗ |